Monitoring breast cancer treatment response using circulating tumor DNA
Circulating Tumor DNA to Monitor Response to Neoadjuvant Chemotherapy in Breast Cancer
This study tests if measuring circulating tumor DNA can help women with breast cancer see how well their chemotherapy is working before surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | Female |
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Guandong, Guangdong) |
| Trial ID | NCT03260192 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the effectiveness of circulating tumor DNA as a marker to assess how well patients respond to neoadjuvant chemotherapy for breast cancer. Neoadjuvant chemotherapy is used to shrink tumors before surgery, and accurately monitoring treatment response is crucial for optimizing patient outcomes. The study will involve female patients aged 18-70 who are undergoing this type of chemotherapy, evaluating their circulating tumor DNA levels throughout the treatment process.
Who should consider this trial
Good fit: Ideal candidates for this study are female patients aged 18-70 undergoing neoadjuvant chemotherapy for breast cancer.
Not a fit: Patients with metastatic disease discovered during neoadjuvant chemotherapy or those who have lost more than two blood samples during the study will not benefit.
Why it matters
Potential benefit: If successful, this approach could provide a more accurate and less invasive method for monitoring treatment response in breast cancer patients.
How similar studies have performed: Other studies have shown promise in using circulating tumor DNA for monitoring treatment response, suggesting this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female patients undergoing NAC * Age: 18-70 yrs * Any menopausal status * Any hormal receptor status Exclusion Criteria: * Metastasis discovered during NAC * Lost more than 2 blood samples during NAC and surgery
Where this trial is running
Guandong, Guangdong
- Sunyat-sen Memorial Hospital — Guandong, Guangdong, China (Recruiting)
Study contacts
- Principal investigator: qiang Liu — Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Study coordinator: Shunying Li
- Email: lishunying@foxmail.com
- Phone: +86-15915939702
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.